latest libr head ada
ahead american diabet associ ada confer orlando start
today opportun catch abbott check number
diabetes-specif gener abbott topic follow recent diabet survey
click read posit physician recept on-going us
launch freestyl libr continu view technolog advoc
greater adopt glucos sensor categori whole rather threat
incumb cgm provid interest takeaway
discuss look ahead next-gen consum libr product could look
dexcom-lik function alert alarm etc afford
continu number one prioriti outsid diabet confirm
enact propos chines tariff wont much differ
impact call first round tariff may trucker strike
brazil immateri impact final adjust model
account strengthen usd abbott issu guidanc first
quarter report april today result top-lin move lower
year manag assum
wide rang fx rate ep guidanc bottom-lin remain unchang
abbott wont host analyst event ada expect hear lot
libr weekend freestyl libr flash glucos monitor continu
one import product space sinc septemb
fda approv global product well user sign
new patient pace retent rate vast major
patient tri glucos sensor technolog first time rather
convert today compani see
patient mix movement greater complexion patient
time expect make sens given libr profil function
next-gener libr like sophist featur low
cost easi use still prioriti first gener freestyl libr
serv excel solut frequent test beyond bgm diabet
given simplic non-invas form factor abbott aspir
offer sophist offer closer true cgm abbott wouldnt
specifi timelin upgrad featur addit target futur libr
gener includ alert similar cgm bluetooth connect extend
wear life day us vs day ou shorter warm time
current hour vs dexcom hour
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
abbott confid offer feature-enhanc freestyl libr without
significantli chang cost product perhap attract featur
abbott freestyl libr flash glucos meter today price sensor
cost patient out-of-pocket assum co-pay price
structur pharmaci less pharmaci co-pay abbott appreci cost
major appeal freestyl libr insist featur upgrad impli
signific cost upcharg enter consum glucos monitor space
compani view afford chief barrier greater sensor util
sentiment remain core part strategi
catalyst horizon includ pediatr label expans
file fda approv expect ye closed-loop system bigfoot
biomed asid next-gener sensor timelin
specifi anoth upcom catalyst compani expans us
pediatr popul current product approv patient older
abbott file label cover usag product patient two year
expect year end final integr system environ
abbott partnership privately-held bigfoot biomed two compani
announc collabor last juli bigfoot util abbott freestyl libr
glucos sensor compon integr pump/pen-sensor system
meet member bigfoot manag team ada weekend
discuss updat around timelin design diabet platform
recent concern around brazilian trucker strike potenti chines tariff
expect materi impact abbott financi brazil
countri abbott signific sale manufactur exposur therefor
isnt expect materi impact trucker strike may china
compani wouldnt classifi potenti tariff complet non-ev didnt see
impact includ latest round tariff much wors
mention earlier year call
updat forecast account strengthen dollar
last two month result headwind sale rel neutral
ep abbott last issu guidanc earn call april
usd/eur spot rate usd sinc appreci
usd/eur rate abbott currenc adjust alon lower report
top-lin outlook accordingli
model fx provid tailwind previous
tailwind full year fx turn headwind
bottom-lin abbott assum wide rang outcom fx
movement mean compani expect off-set impact ep
throughout call abbott expect fx cent
tailwind bottom-lin stronger dollar impact closer
neutral ep howev despit modest ep headwind abbott expect off-set
impact fx doesnt see need ep number move
lower currenc
invest thesi valuat risk
fundament abbott remain solid end market perform well organ
growth expect reach high end organ growth back
multipl new product launch includ us launch freestyl
libr glucos monitor system alin famili next-gener core lab
system heartmat left ventricular assist system confirm rx
implant cardiac monitor icm compet mdt linq mri
compat icd crt-d close competit gap strong
top line year deal accret st jude plu year aler turn
organ sale growth ep growth reinvest
even room potenti upsid come compani abil access
ou cash post tax reform accret debt paydown
backdrop reiter overweight rate abbott
decemb price target valu share ep
ebitda modest premium vs peer trade today roughli
ep ebitda feel appropri given
abbott top- bottom-lin growth outlook upsid potenti see
street estim come year
risk rate price
downsid risk rate includ abbott macro exposur emerg
market poor integr failur stabil aler busi
potenti pipelin new product launch disappoint
abbott laboratori summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
